Simulations Plus - SLP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $56.00
  • Forecasted Upside: 79.26%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$31.24
▲ +0.88 (2.90%)

This chart shows the closing price for SLP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Simulations Plus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLP

Analyst Price Target is $56.00
▲ +79.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Simulations Plus in the last 3 months. The average price target is $56.00, with a high forecast of $65.00 and a low forecast of $47.00. The average price target represents a 79.26% upside from the last price of $31.24.

This chart shows the closing price for SLP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Simulations Plus. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/12/2024William BlairReiterated RatingOutperform
7/29/2024KeyCorpInitiated CoverageOverweight$47.00
7/16/2024JMP SecuritiesInitiated CoverageMarket Perform
7/3/2024Craig HallumReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
6/28/2024William BlairInitiated CoverageOutperform
6/13/2024Craig HallumBoost TargetBuy ➝ Buy$51.00 ➝ $56.00
6/13/2024OppenheimerBoost TargetOutperform ➝ Outperform$55.00 ➝ $65.00
1/4/2024Craig HallumBoost TargetBuy ➝ Buy$50.00 ➝ $51.00
5/9/2023BTIG ResearchInitiated CoverageBuy$55.00
4/6/2023OppenheimerReiterated RatingOutperform$65.00
10/27/2022Craig HallumLower Target$56.00
10/27/2022OppenheimerLower Target$75.00 ➝ $65.00
8/29/2022Raymond JamesBoost TargetOutperform$54.00 ➝ $70.00
7/7/2022Craig HallumBoost TargetBuy$55.00 ➝ $60.00
1/4/2022SidotiInitiated CoverageNeutral ➝ Neutral
10/26/2021Craig HallumUpgradeHold ➝ Buy$65.00 ➝ $53.00
7/13/2021OppenheimerReiterated RatingBuy$75.00
7/13/2021Craig HallumLower TargetHold$74.00 ➝ $65.00
7/13/2021Raymond JamesLower TargetOutperform$95.00 ➝ $54.00
4/13/2021Craig HallumLower TargetHold$81.00 ➝ $74.00
1/12/2021OppenheimerBoost Target$79.00 ➝ $85.00
1/12/2021Craig HallumDowngradeBuy ➝ Hold
11/25/2020Taglich BrothersUpgradeSpeculative Buy ➝ Buy$76.00
11/17/2020Craig HallumBoost TargetBuy$75.00 ➝ $81.00
10/16/2020Raymond JamesInitiated CoverageOutperform$95.00
9/8/2020OppenheimerInitiated CoverageOutperform$79.00
7/10/2020Craig HallumBoost TargetBuy$56.00 ➝ $75.00
6/8/2020Craig HallumBoost TargetBuy$40.00 ➝ $56.00
1/6/2020Craig HallumInitiated CoverageBuy$40.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/16/2024
  • 11 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/14/2024
  • 11 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/13/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/12/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
10/12/2024

Current Sentiment

  • 7 very positive mentions
  • 7 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $31.24
Low: $30.30
High: $31.35

50 Day Range

MA: $34.02
Low: $29.82
High: $38.60

52 Week Range

Now: $31.24
Low: $29.37
High: $51.22

Volume

118,487 shs

Average Volume

122,643 shs

Market Capitalization

$625.05 million

P/E Ratio

65.08

Dividend Yield

0.79%

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Simulations Plus?

The following equities research analysts have issued stock ratings on Simulations Plus in the last twelve months: Craig Hallum, JMP Securities, KeyCorp, Oppenheimer Holdings Inc., and William Blair.
View the latest analyst ratings for SLP.

What is the current price target for Simulations Plus?

3 Wall Street analysts have set twelve-month price targets for Simulations Plus in the last year. Their average twelve-month price target is $56.00, suggesting a possible upside of 79.3%. Oppenheimer Holdings Inc. has the highest price target set, predicting SLP will reach $65.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $47.00 for Simulations Plus in the next year.
View the latest price targets for SLP.

What is the current consensus analyst rating for Simulations Plus?

Simulations Plus currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SLP.

What other companies compete with Simulations Plus?

Other companies that are similar to Simulations Plus include Ebix, Verint Systems, NetScout Systems, Veradigm and ECARX. Learn More about companies similar to Simulations Plus.

How do I contact Simulations Plus' investor relations team?

Simulations Plus' physical mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company's listed phone number is (661) 723-7723 and its investor relations email address is [email protected]. The official website for Simulations Plus is www.simulations-plus.com. Learn More about contacing Simulations Plus investor relations.